|
[1]
|
Diagnosestellung eines „cancer of unknown primary“
Die Onkologie,
2024
DOI:10.1007/s00761-024-01478-2
|
|
|
|
|
[2]
|
Holland‐Frei Cancer Medicine
2022
DOI:10.1002/9781119000822.hfcm124.pub2
|
|
|
|
|
[3]
|
Holland‐Frei Cancer Medicine
2022
DOI:10.1002/9781119000822.hfcm124.pub2
|
|
|
|
|
[4]
|
A Novel XGBoost Method to Infer the Primary Lesion of 20 Solid Tumor Types From Gene Expression Data
Frontiers in Genetics,
2021
DOI:10.3389/fgene.2021.632761
|
|
|
|
|
[5]
|
New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
Critical Reviews in Oncology/Hematology,
2020
DOI:10.1016/j.critrevonc.2020.102882
|
|
|
|
|
[6]
|
Rationelle Diagnostik und Therapie in der Inneren Medizin
2020
DOI:10.1016/B978-3-437-06282-7.50009-7
|
|
|
|
|
[7]
|
Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine
American Society of Clinical Oncology Educational Book,
2018
DOI:10.1200/EDBK_100014
|
|
|
|
|
[8]
|
The American Cancer Society's Oncology in Practice
2018
DOI:10.1002/9781118592168.ch44
|
|
|
|
|
[9]
|
Cancer of Unknown Primary
2016
DOI:10.1007/978-3-319-22581-4_11
|
|
|
|
|
[10]
|
Diagnosis: Improved diagnosis, therapy and outcomes for patients with CUP
Nature Reviews Clinical Oncology,
2016
DOI:10.1038/nrclinonc.2016.194
|
|
|
|
|
[11]
|
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)
Annals of Oncology,
2016
DOI:10.1093/annonc/mdv543
|
|
|
|
|
[12]
|
Cancer of Unknown Primary
2016
DOI:10.1007/978-3-319-22581-4_11
|
|
|
|
|
[13]
|
Gene expression profiling and its use in adenocarcinomas of unknown primary origin: A case report
Oncology Letters,
2015
DOI:10.3892/ol.2015.3572
|
|
|
|
|
[14]
|
Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial
Cancer,
2015
DOI:10.1002/cncr.29229
|
|
|
|
|
[15]
|
Reference Module in Biomedical Sciences
2015
DOI:10.1016/B978-0-12-801238-3.98750-6
|
|
|
|
|
[16]
|
SpringerReference Innere Medizin
2015
DOI:10.1007/978-3-642-54676-1_494-1
|
|
|
|
|
[17]
|
Atlas of PET-CT Imaging in Oncology
2015
DOI:10.1007/978-3-319-18994-9_8
|
|
|
|
|
[18]
|
Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial
Cancer,
2015
DOI:10.1002/cncr.29229
|
|
|
|
|
[19]
|
Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care
Virchows Archiv,
2014
DOI:10.1007/s00428-014-1545-2
|
|
|
|
|
[20]
|
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
Journal of Clinical Oncology,
2013
DOI:10.1200/JCO.2012.43.3755
|
|
|
|
|
[21]
|
Molecular Diagnosis of the Tissue of Origin in Cancer of Unknown Primary Site: Useful in Patient Management
Current Treatment Options in Oncology,
2013
DOI:10.1007/s11864-013-0257-1
|
|
|
|
|
[22]
|
Cancer of Unknown Primary Site: Improved Patient Management with Molecular and Immunohistochemical Diagnosis
American Society of Clinical Oncology Educational Book,
2013
DOI:10.14694/EdBook_AM.2013.33.175
|
|
|
|